Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Key Takeaways

• Four‑year contract with France’s EFS for INTERCEPT platelets and plasma.
• Covers next‑gen LED INT200 illumination device alongside existing system.
• EFS handles ~330,000 platelet units annually across 13 French regions.
• INTERCEPT used in French overseas territories to counter arbovirus outbreaks.
• Deal strengthens Cerus’ foothold in Europe and supports INT200 rollout.

Pulse Analysis

Cerus’ agreement with the French Blood Establishment (EFS) marks a strategic win in a market where pathogen‑inactivation technology is increasingly essential. With regulatory approvals from both the FDA and the European CE mark, INTERCEPT remains the only system that can treat platelets and plasma while meeting stringent safety standards. The partnership not only guarantees a steady demand stream but also validates Cerus’ technology in a mature European health system, where blood safety concerns have intensified after recent arbovirus outbreaks.

EFS’s distribution network spans 13 mainland regions and several overseas territories, handling roughly 330,000 platelet units annually. Those territories—such as La Réunion, Guadeloupe, and Martinique—have faced recurring threats from chikungunya, dengue and Zika, making pathogen‑reduced blood products a public‑health priority. By extending INTERCEPT’s reach into these high‑risk zones, Cerus helps maintain a resilient blood supply, reducing the risk of transfusion‑transmitted infections and supporting emergency response capabilities during epidemic spikes.

Financially, the four‑year supply contract adds a predictable revenue pillar for Cerus, complementing its U.S. sales and ongoing clinical programs for red blood cells. The inclusion of the next‑generation INT200 illumination device signals a push toward higher‑throughput, energy‑efficient operations, potentially lowering operating costs for blood centers. As European regulators continue to scrutinize pathogen‑reduction solutions, Cerus’ proven track record and expanded footprint position it to capture additional national contracts and accelerate the rollout of INT200 across new geographies. The deal therefore serves as both a revenue catalyst and a platform for broader market penetration.